VEGFA and neoplasm: There was a possible association between the degree of change in tumour perfusion measured after 2 weeks of therapy and subsequent clinical benefit (t test, p = 0.05; Figure 4a) as well as with duration of therapy (Figure 4b) and with change in biomarker levels, particularly VEGF (Figures 5b,c).